HIV in 2014 A CME Debate Series

Program Overview:

The treatment of people with HIV infection is rapidly and constantly progressing. With many antiretrovirals (ARVs) and ARV combinations available, clinicians caring for HIV-positive patients have increasingly complex choices regarding ARV therapy. While these medications provide important options for treating patients with HIV infection, they also present new challenges, because it is not always possible for clinicians to keep up with the flood of information available that they need to provide optimal, individualized care. This situation can contribute to increased morbidity and mortality in HIV-positive patients. To address this problem, the HIV in 2014 program provides a series of quarterly CME dinner programs in six major cities in the United States. The winter series will feature an update from the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2014) and the HIV Drug Therapy Glasgow Meeting (HIV 11).

The two-hour programs will feature one national level faculty and one program moderator who will present and discuss key topics in HIV patient care. These case-based programs will provide new clinical information that will help health care providers address knowledge gaps concerning the treatment of a wide range of patient types and treatment scenarios. The audience will receive the knowledge needed to address professional practice gaps, which should result in more individualized therapy, fewer long-term adverse effects, improved adherence, and reduced viral loads, and ultimately to a reduction in morbidity and mortality.

Target Audience:

This activity is intended for physicians, physician assistants, advanced practice nurses, and other health care professionals actively involved in the treatment and management of patients with HIV-infection. It is tuition-free and there are no prerequisites.

Commercial Support Acknowledgement:

This activity is supported by an unrestricted educational grant by Gilead Sciences Medical Affairs.

Educational Objectives:

Upon completion of the activity, participants should be able to:

Initiate current ARV drug options available for treatment-naïve patients with HIV based upon major guideline recommendations and current clinical research findings

Incorporate appropriate and effective therapeutic strategies in the management of treatment-experienced patients with HIV
Use information regarding drug adverse events, drug pharmacokinetics and patient adherence to achieve ARV success and avoid morbidity and mortality

Describe preventive care and treatment for the important opportunistic infections and co-morbidities that may increase the risk for morbidity and mortality in HIV positive patients

Describe the importance of individualizing the care of each HIV-positive patient in clinical practice

Course Directors and Program Faculty:

Calvin J. Cohen, MD, MS
Research Director
CRI New England
Clinical Instructor,
Harvard Medical School
Boston, Massachusetts

Ian Frank, MD
Professor of Medicine
Director, Clinical Therapeutics Program
Penn Center for AIDS Research
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania

Program Moderators:

Roberto C. Arduino, MD Professor of Medicine, UT Director of Research, Thomas Street Clinic The University of Texas-Houston Houston, Texas	Lisa Capaldini, MD Assistant Clinical Professor of Medicine, University of California San Francisco School of Medicine San Francisco, California
Anthony Mills, MD Medical Director, Southern California Men's Medical Group Executive Director, Men's Health Foundation Principle Investigator, Mills Clinical Group Assistant Professor of Clinical Medicine, UCLA Los Angeles, California	Renslow Sherer, MD Professor of Medicine, Section of Infectious Diseases and Global Health University of Chicago Chicago, Illinois
Michael Sension, MD Physician, Comprehensive Care Center Ft. Lauderdale, Florida	Antonio A. Urbina, MD Associate Medical Director, Center for Comprehensive Care West Village Division St. Luke's Roosevelt Hospital New York, New York

Dates/Cities - Winter:

Tuesday, November 11, 2014 Los Angeles, CA	Wednesday, November 12, 2014 Houston, TX
Wednesday, November 12, 2014 Chicago, IL	Thursday, November 13, 2014 New York, NY
Thursday, November 13, 2014 San Francisco, CA	Wednesday, November 19, 2014 Miami, FL

Schedule for all Programs:

6:00 - 6:30 PM Check-in/Walk-in Registration
6:30 - 8:30 PM Program and Q&A

Sunshine Act:

As of August 1, 2013, pharmaceutical companies are required by the open payments act (AKA Sunshine Act) to account for certain transfers of value provided to physicians. The federal guidance for the Sunshine Act provides exceptions for CME expenses that meet certain criteria. We believe the program to which you are invited meets these exceptions, and therefore we will not be collecting, nor reporting, any information gathered from this program. If federal guidance is further clarified in the future, we will then provide that information to the supporting pharmaceutical companies to the best of our ability.

Accreditation Statement:

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and ViralEd, Inc. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:

The Postgraduate Institute for Medicine designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest:

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.